LENASAB (Lenalidomide) is classified as an “immunomodulatory agent” and an “antiangiogenic agent”. It works by enhancing the immune system that indirectly attacks the cancer cells. It prevents the growth of new blood vessels within the tumor. It also restricts the production of chemical messengers (cytokine and growth factor) which are responsible for the growth of cancer cells.
It is used in;
Treatment of Multiple Myeloma
Treatment of transfusion-dependent myelodysplastic syndrome (MDS) patients with deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Treatment of Mantle Cell Lymphoma (MCL)
In combination with a rituximab product for previously treated follicular lymphoma or marginal zone lymphoma